Insomnia Market Trending in Europe, the Middle East and Africa Region by 2023; Sanofi, Astellas, Biocodex S A, Neurim and More

Europe, the Middle East and Africa Insomnia Market Research Report, By Types of Therapy (Pharmacological Therapy and Non-Pharmacological Therapy), By Drug Formulation (Capsules, Tablet and Others), By Type of Diseases Condition (Poor Quality of Sleep, Sleep Maintenance and Other) - Forecast Till 2023

Insomnia is the most common disorder in Europe, Middle East and Africa. Large number of people suffer from insomnia in these regions. Europe, the Middle East and Africa insomnia market is driven mainly because of increasing insomnia patients principally due to increasing workload and pressure, changing lifestyle and high incident of mental disorders which favor the growth of this market. Anxiety and depression also contribute to an increase in the market of insomnia. Increasing prevalence of neurological disorders favor the growth of the market. Emphasis on awareness and education of insomnia regarding its symptoms and causes also boost this market.

The Europe, the Middle East and Africa Insomnia Market is expected to grow at a CAGR of 4.28% during forecasted period of 2017-2023.

Competitive Analysis:

Pfizer Inc. (U.K), Sanofi (France), GlaxoSmithKline Plc. (UK), Astellas (UK), Biocodex S A (France), Neurim (Switzerland). Others players are Flynn Pharma (UK) CAD Middle East Pharmaceutical Industries LLC (Saudi Arabia), Tabuk Pharmaceutical (Jordan).

Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including cardiology, oncology, diabetology, neurology and immunology. Indiplon is a drug manufactured by Pfizer for insomnia. Pfizer, Inc. is a US headquartered pharmaceutical company. SONATA is one of the major product of this company. Company is focusing on the development of the new sleeping pills. Company has successfully completed the phase 4 study of Pristiq for the treatment of depressive disorders.

Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/594 .

Sanofi is a global life science company. It manufactures drugs for immunology, cardiology, diabetes, oncology and other healthcare specialties. Zolpidem is a drug manufactures by the company for insomnia. The study of effect of this drug on people with insomnia was carried by the company in 2007.

GlaxoSmithKline Plc. is a global pharmaceutical company manufacturing and marketing the products and solutions in healthcare industry. In 2008. The company collaborated with Acetelion to conduct clinical trials on orexin receptor antagonist for insomnia. In 2011, the company stopped these trails as a safety concern as the subjects were unable to tolerate the dose of medicine.

Neurim is a drug discovery and development company. The company mainly focuses on insomnia and neurogenetic diseases to improve the quality of life of the patients. “Circadin”” was the first approved drug for insomnia.

Segmentation:

Europe, the Middle East and Africa insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other.

Grab Attractive Discount @ https://www.marketresearchfuture.com/check-discount/594 .

Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioral therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.

…Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.